On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). He shares the promising results of the company’s proprietary BMB-101 drug to treat a rare form of epilepsy, Dravet Syndrome. The chief officer also talks about the firm’s plan to list on the Nasdaq, the common misconceptions on psychedelics, and the overall outlook of the biotech company in the medical space.
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs.
FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
Is Bitcoin A Fraud? – The Daily Dive feat Jeff Wareham
Today on the Daily Dive, we’re joined by Jeff Wareham, whom is a director at...